The present study addressed links between progestin and heregulin (HRG) signaling pathways in mammary tumors. An experimental model of hormonal carcinogenesis, in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in female Balb/c mice, was used. MPA induced an in vivo up-regulation of HRG mRNA expression in progestin-dependent (HD) tumor lines. Mammary tumor progression to a progestin-independent (HI) phenotype was accompanied by a high constitutive expression of HRG. The HRG message arose from the tumor epithelial cells. Primary cultures of malignant epithelial cells from a HD tumor line were used to investigate HRG involvement on cell proliferation. HRG induced a potent proliferative eect on these cells and potentiated MPA mitogenic eects. Blocking endogenous HRG synthesis by antisense oligodeoxynucleotides (ASODNs) to HRG mRNA inhibited MPA-induced cell growth, indicating that HRG acts as a mediator of MPA-induced growth. High levels of ErbB-2 and ErbB-3 expression and low ErbB-4 levels were found in HD cells. Treatment of these cells with either MPA or HRG resulted in tyrosine phosphorylation of both ErbB-2 and ErbB-3. Furthermore, both HRG and MPA proliferative eects were abolished when cells were treated with ASODNs to ErbB-2 mRNA, providing evidence for a critical role of ErbB-2 in HRG-induced growth. Finally, blocking type I insulin-like growth factor receptor (IGF-IR) expression with ASODN resulted in the complete inhibition of HRG proliferative eect, demonstrating that a functional IGF-IR is required for HRG mitogenic activity. These results provide the ®rst evidence of interactions between progestins and HRB/ErbB signal transduction pathways in mammary cancer and the ®rst demonstration that IGF-IR is required for HRG proliferative eects.
Introduction
The Neu Dierentiation Factor (NDF) or Heregulin (HRG) family includes a series of polypeptides sharing an epidermal growth factor-(EGF)-like motif that acts as the receptor binding domain Wen et al., 1994) . According to the structure of this motif, two major subclasses of HRG variants, a and b, can be distinguished (Carraway and Cantley, 1994) . HRG exerts multiple physiological actions through a unique combinatorial signaling. Two members of type I receptor tyrosine kinase family (RTKs-I), ErbB-3 and ErbB-4, mediate HRG functions (Carraway and Cantley, 1994) . The other RTKs-I family members, ErbB-1 (or EGF-R) and ErbB-2, are the co-receptors (Pinkas-Kramarski et al., 1997) . Activation of RTKs-I by HRG initiates signal transduction cascades involved in cellular responses such as proliferation and dierentiation. HRG treatment of breast cancer cells induces activation of the Erk/MAP kinases (Marte et al., 1995a; Sepp-Lorenzino et al., 1996) , Jnk/SAP kinases (stress activated protein kinases) (Amundadottir and Leder, 1998) , p70/p85 S6 kinase (Marte et al., 1995a) and phosphatidyl inositol 3-kinase (PI-3K) (Sepp-Lorenzino et al., 1996; Amundadottir and Leder, 1998) . Particularly interesting is the role of ErbB-3 in PI-3K activation, since ErbB-3 possesses the unique capacity among RTKs-I to bind the p85 regulatory subunit of PI-3K (Carraway and Cantley, 1994; Fedi et al., 1994; Graus-Porta et al., 1997) . ErbB-3 ability to associate with PI-3K confers to this receptor the possibility of sharing signal transduction pathways with insulin-like growth factors (IGFs), since activation of type I IGF receptor (IGF-IR) results in tyrosine phosphorylation of a substrate protein, IRS-1, which in turn binds to and activates p85 (Backer et al., 1993) .
The biological eects of HRG exhibit variations that depend on cell type, HRG isoform, and cellular complements of RTKs-I available to make up functional heterodimers. Certain HRG isoforms are reported to induce growth-arrest and dierentiation of mammary epithelial cells, while other breast cells respond mitogenically (Yang et al., 1995; Marte et al., 1995b; Ram et al., 1995) . Also, stimulatory (Holmes et al., 1992; Lewis et al., 1996) and inhibitory eects Bacus et al., 1993; Culouscou et al., 1993) of HRG on the proliferation of breast cancer cell lines, expressing dierent levels of ErbB-2, have been reported. In addition, a biphasic eect of HRG on the proliferation of cells overexpressing ErbB-2 has been found. In the cell line BT-474 low doses of HRG induce cell growth and higher doses inhibit proliferation (Grunt et al., 1995) . Further support for HRG involvement in mammary carcinogenesis has been provided by transgenic mice overexpressing HRGb; in these female mice, mammary adenocarcino-mas arise in a stochastic fashion following several pregnancies (Krane and Leder, 1996) .
Links between HRG/ErbB-2 signaling pathway and estrogen receptor (ER) have been described. Treatment of hormone-dependent breast cancer cell lines with HRG results in decreased ER expression at protein and RNA levels (Saceda et al., 1996; Pietras et al., 1995) . However, whether HRG-induced down-regulation of ER is followed by induction (Pietras et al., 1995) or inhibition (Saceda et al., 1996) of ER activity remains controversial. On the other hand, treatment of breast cancer cells with estrogens results in decreased expression of ErbB-2 (Grunt et al., 1995) .
The aim of the present study was to investigate the interactions between progestins and HRG signaling pathways by using the well characterized model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA) induces mammary adenocarcinomas in virgin female Balb/c mice (Molinolo et al., 1987; Lanari et al., 1989) . Most of the MPA-induced tumors are of ductal origin, express high levels of ER and progesterone receptor (PR) and are maintained by syngeneic transplants in MPA-treated mice, showing a progestin-dependent (HD) pattern of growth (Lanari et al., 1989) . By transplantation into untreated mice, tumor variants with an MPA-independent (HI) pattern of growth have been generated. These HI tumors express the same ER and PR content as their parental HD counterparts (Lanari et al., 1989) . Finally, MPA induces a small number of lobular mammary carcinomas which lack ER and PR expression and evidence an MPA-independent (HI) behavior (Molinolo et al., 1987; Lanari et al., 1989) .
We have found that in vivo HRG expression in HD tumors is under MPA control. Mammary tumor progression to a hormone-independent phenotype is accompanied by a high constitutive expression of HRG. We have used primary cultures of epithelial cells from a HD tumor line to study the involvement of HRG on cell growth, and show that HRG stimulates HD cell proliferation and is able to potentiate MPA proliferative eects. MPA and HRG treatment of HD cells results in tyrosine phosphorylation of ErbB-2 and ErbB-3. We blocked both HRG and ErbB-2 expression using antisense oligodeoxynucleotides (ASODN) and demonstrated that HRG acts as mediator of MPAinduced proliferation and that ErbB-2 is essential in this motogenic pathway. Finally, we showed, for the ®rst time according to our knowledge, that a functional IGFR-IR is required for HRG biological activity.
Results
Expression of HRG at the mRNA level in in vivo lines of MPA-induced mammary tumors
In order to obtain homologous probes for the analysis of heregulin expression in mouse mammary tumors, two fragments of the mouse HRG were cloned by using PCR and cDNAs obtained from HD tumors of our experimental model. Sequence analysis of the fragments, localized in the Ig domain (fragment 1) and the cytoplasmic tail domain (fragment 2), showed a high degree of homology with the rat (Wen et al., 1992) (fragment 1: 89%; fragment 2: 92%) and human (Lupu and Lippman, 1993) (fragment 1: 83%; fragment 2: 89%) HRG genes ( Figure 1 ).
HRG expression was studied performing RNAse protection assays, using the fragment localized in the Ig domain of the gene as probe. This probe recognises both HRGa and b isoforms.
Three types of tumors from the MPA-induced model of mammary carcinogenesis were included in this study. The ®rst type were ductal hormone-dependent (HD) tumor lines that require MPA administration for their in vivo growth and express high levels of ER and PR content (Molinolo et al., 1987; Lanari et al., 1989) . The second were their hormone-independent (HI) variants, that are able to grow in absence of MPA administration. These HI ductal tumors, in spite of an MPA-independent pattern of growth, retain ER and PR expression (Molinolo et al., 1987; Lanari et al., 1989) . The third type of tumors analysed were MPAinduced mammary carcinomas of lobular origin that lack ER and PR expression and evidence a HI behavior (Molinolo et al., 1987; Lanari et al., 1989) .
HRG mRNA in vivo expression was found in ductal HD tumor lines C4, D5 and 53. A signi®cant increase (2 ± 5-fold) of HRG mRNA levels was detected in tumors growing in MPA-treated mice, as compared with HD tumors growing in untreated animals (Figure 2a, b) . HRG message was also detected in the HI variants of ductal origin, C4HI, D5HI, and 53HI, with similar levels to those observed in HD tumors growing in MPA-treated mice (Figure 2a,b) . HRG mRNA was not found in HI lines of lobular histology 39, 55, 60 and 52B (Figure 2a ).
Cellular localization of HRG message
To identify the cellular origin of HRG, RNAs obtained from primary cultures of epithelial and ®broblastic Figure 1 Mouse HRG sequence. Nucleotide sequence of the cDNAs cloned fragments 1 and 2 and comparison between mouse, rat, and human HGF genes. Dierences in HRG nucleotide sequence between species are indicated with bold letters. Dashes indicate gaps that were introduced for optimal alignment tumor cells were subjected to RNAse protection assays. HRG mRNA expression was limited to cells of epithelial origin. Representative results in 59HD and C4HD tumors are shown in Figure 2c .
Involvement of HRG on the proliferation of primary cultures of C4HD tumor line C4HD tumor line was selected to study HRG involvement in in vitro growth because it has exhaustively been characterized as regard to its in vitro proliferative behavior and response to MPA (Dran et al., 1995) . C4HD epithelial cells proliferate very slowly in absence of MPA treatment, retain PR expression and the exquisite sensitivity to MPA proliferative eect shown by the in vivo tumor line (Dran et al., 1995) . Therefore, all the characteristics showed by C4HD tumor in vivo growth are maintained in this primary culture system. In addition, C4HD line express the lower level of endogenous HRG among all HD lines studied, making it possible to detect biological eects when HRG is exogenously added.
ErbB receptor expression
We ®rst investigated the cellular complements of ErbB receptors expressed in C4HD cells. Western blots were performed on whole C4HD cell lysates with antibodies to ErbB-2, ErbB-3 and ErB-4. As control for levels of ErbB-2 expression we used the human breast cancer MCF-7 cell line that contains low ErbB-2 levels. C4HD cells expressed signi®cantly higher levels of ErbB-2 than MCF-7 cells (3 ± 5-fold), comparable with those considered as overexpression in human breast cancer cell lines (Figure 3 ) (Lupu and Lippman, 1993) . High levels of ErbB-3 expression were also found in C4HD cells. Our analysis of ErbB-4, using a panel of ErbB-4 speci®c antibodies, indicated low ErbB-4 expression levels.
HRG stimulates the proliferation of epithelial cultures of C4HD tumor line HRGb1, at concentrations ranging from 0.02±200 ng/ ml, was added to C4HD epithelial tumor cells and incorporation of [ Figure  5a ) nor scrambled oligos (data not shown) had any eect on cell growth. Growth of C4HD cells in 2.5% steroid-stripped fetal calf serum (ChFCS) was also inhibited by ASODNs (Figure 5a ). There was no evidence of toxicity in response to ODNs as determined by loss of cells into the medium. The eect of HRG ODNs on HRG expression was assessed by immunoblotting C4HD cell lysates. Densitometric evaluation demonstrated that HRG levels were reduced by 65 ± 76% after 4 mM ASODNs treatment, while SODNs did not reduce HRG levels ( Figure 5b ).
Tyrosine phosphorylation of ErbB family of receptors
In order to extend our observations that HRG might act as a mediator of MPA proliferative eects, we studied the level of tyrosine phosphorylation of ErbB receptors as a marker of their activation. Therefore, extracts from C4HD cells treated with either MPA or HRG were immunoprecipitated with anti ErbB-2 or ErbB-3 antibodies and the phosphotyrosine content of these receptors was determined by performing Western blotting with an anti-phosphotyrosine antibody. Figure 6 shows that while tyrosine phosphorylation of both receptors was undetectable in cells growing in 2.5% ChFCS, MPA and HRG, after 48 h of treatment, induced a strong phosphorylation of both ErbB-2 and ErbB-3. Increase of tyrosine phosphorylation of ErbB-2 and ErbB-3 by HRG treatment was seen as early as 10 min after the addition of HRG (data not shown).
Antisense oligodeoxynucleotides to ErbB-2 mRNA inhibit both HRG and MPA-induced proliferation of C4HD cells
Incubation of C4HD cells with ASODNs to ErbB-2 mRNA inhibited HRG-mediated proliferation ( Figure  7a ). Since our results indicate that MPA-induced growth of C4HD cells is mediated by HRG, through the activation of ErbB-2 and ErbB-3, we next investigated whether ErbB-2 is a critical component in this signaling pathway. Incubation of C4HD cells with ASODNs to ErbB-2 mRNA resulted in a dosedependent inhibition of MPA-mediated cell proliferation. (Figure 7a ). Sense ODNs had no eect on cell growth. (Figure 7a ). The eect of ErbB-2 ODNs on protein expression was assessed by immunoblotting C4HD cell lysates. Figure 7b shows the results obtained when ASODNs were used to inhibit MPAinduced proliferation. Densitometric evaluation demonstrated that ErbB-2 levels were reduced by 68% after 2 mM ASODNs treatment, while SODNs did not reduce ErbB-2 levels. Similar inhibition of ErbB-2 protein expression was obtained when ASODNs were used to inhibit HRG-stimulated growth. When then investigated whether blocking ErbB-2 by ASODNs had any eect on the level of ErbB-3 or ErbB-4 protein expression. Figure 7c ,d shows that neither ErbB-3 nor ErbB-4 protein levels were aected by inhibition of ErbB-2 expression.
Antisense oligodeoxynucleotides to type I insulin-like growth factor receptor (IGF-IR) mRNA block HRG-induced proliferation of C4-HD cells
We have previously demonstrated by using antisense oligodeoxynucleotides to IGF-IR mRNA, that a functional IGF-IR is required for MPA-induced proliferation of HD cells (Elizalde et al., 1998) . Therefore, we decided to investigate whether HRG also required the presence of a functional IGF-I receptor for its mitogenic activity. Induction of ErbB-2 and ErbB-3 tyrosine phosphorylation by MPA and HRG. Primary cultures of epithelial cells from C4HD tumors were treated for 48 h with either 10 nM MPA or 2 ng/ml HRG or left untreated growing in 2.5% ChFCS. Cells were lysed, ErbB-2 and ErbB-3 were immunoprecipitated from 200 mg of total proteins and immunocomplexes were subjcted to SDS ± PAGE (6% gel) and analysed by Western blotting with an anti-P-Tyr mAb (a and c). Identical aliquots of each immunoprecipitate were subjected to immunoblot analysis with anti-ErbB-2 (b) or anti-ErbB-3 (d) antibodies to verify that nearly equal amount of immunoprecipitated proteins were loaded. W, Western blot; IP, immunoprecipitation 
Discussion
In this work, we have detected HRG expression in in vivo, lines of the MPA-induced mammary tumor model in Balb/c mice (Molinolo et al., 1987; Lanari et al., 1989) . HRG message was con®ned to tumors of ductal origin, ER and PR positive, since HRG mRNA was not found in tumors of lobular histology that lack steroid hormone receptors. HRG mRNA expression has been studied in a small number of primary human breast carcinomas (Normanno et al., 1993 (Normanno et al., , 1995 and no correlation between its expression, nodal status, EGF-R or ErbB-2 presence has been reported (Normanno et al., 1993 (Normanno et al., , 1995 . Other authors have described an association between HRG expression and absence of metastasis to the lymph nodes in human breast tumors . HRG mRNA synthesis was found to be very restricted in breast cancer cell lines (Normanno et al., 1993; Lupu and Lippman, 1993) and was unaected by 17b-estradiol in MCF-7 cells (Normanno et al., 1993) .
We found that MPA induced an in vivo upregulation of HRG mRNA levels in HD lines. Although to our knowledge this is the ®rst report exploring progestin regulation of HRG synthesis in mammary cancer, Yang et al. (1995) have shown that HRG expression in the mouse mammary gland is under tight hormonal control. HRG is expressed in mesenchymal cells adjacent to the ductal epithelium during lobulo-alveolar development in pregnancy. No HRG mRNA was measured during the virginal period and expression sharply decreased during lactation and was absent during involution (Yang et al., 1995) . These ®ndings, like ours, suggest that progesterone controls the synthesis of HRG. However, in our mammary tumor model, the source of HRG is the malignant epithelial cells, which also express HRG receptors ErbB-3 and ErbB-4 and the co-receptor ErbB-2. Thus, the switch from a paracrine role of HRG in normal mammary gland to an autocrine role in mammary cancer, could re¯ect a subversion of the normal growth control mechanisms which results in a proliferative advantage for tumor cells.
Progression to a hormone-independent phenotype of ductal tumors was accompanied by a high constitutive expression of HRG. This ®nding is in accordance with previous results (Pietras et al., 1995) demonstrating that stable transfection of MCF-7 cells with a full length HRG b1 cDNA, conducting to overexpression of HRG, enabled MCF-7 transfected cells to grow in athymic, ovariectomized mice without estrogen supplementation. Similarly, estrogen independent growth and antiestrogen resistance in vitro and in vivo, were obtained when MCF-7 cells were transfected with HRG-b2 cDNA (Tang et al., 1996) . In addition, it was demonstrated that either transfection of MCF-7 cells with HRG cDNA or treatment of these cells with HRG elicited a signi®cant decrease in ER expression at the protein and mRNA level (Pietras et al., 1995; Saceda et al., 1996) . Prolonged exposure of MCF-7 cells to HRG also resulted in a reduction of PR content (Pietras et al., 1995) . In this regard, it is worth noting that in our in vivo model, progression to a hormone-independent phenotype, that is associated with a high constitutive expression of HRG, does not involve any change in either the number or the anity of ER or PR.
The in vitro studies of the eects of exogenous HRG on the growth of primary cultures of C4HD epithelial cells showed that HRG is able to induce a proliferative response as potent as MPA on these cells. In addition, HRG potentiated MPA stimulatory eects. It remains to be elucidated whether HRG proliferative eects and potentiation of MPA-induced growth involves activation of progesterone receptor, as has been reported for estrogen receptor (Pietras et al., 1995) . HRG participation as mediator of MPA-induced growth of C4HD cells was demonstrated by using an antisense strategy to HRG mRNA in which blocking endogenous HRG by ASODNs inhibited MPA-induced cell growth.
The biological eects of HRG may be attributable in part to the cellular complements of class I RTKs available to make up functional heterodimers. In C4HD cells we found high levels of ErbB-2 and ErbB-3 and very low levels of ErbB-4 expression. We have previously demonstrated that these cells lack ErbB-1 (Lanari et al., 1989) . Treatment of C4HD cells with HRG induced tyrosine phosphorylation of both ErbB-2 and ErbB-3. Incubation with MPA, that induced an upregulation of HRG levels, also resulted in tyrosine phosphorylation of ErbB-2 and ErbB-3. These results provide further support for a role of HRG as mediator of MPA-proliferative eects, since HRG produced in response to MPA could be the ligand responsible for ErbB-2 and ErbB-3 phosphorylation.
Several reports have established that ErbB-2 is a critical component in mediating HRG-induced breast cancer cells growth. HRG stimulation of MCF-7 and T-47D cells growth was inhibited by anti-ErbB-2 monoclonal antibodies (Lewis et al., 1996) . A dierent approach, based on the intracellular retention of ErbB-2 by using a single-chain ErbB-2 antibody also demonstrated that stimulation of growth by HRG was dramatically impaired in T-47D and MCF-7 cells (Berlii et al., 1995) . The results presented herein, demonstrating that HRG-induced growth is abolished by ErbB-2 ASODNs indicate that, in our model system, ErbB-2 is essential in HRG signaling pathway. We have also found that MPAinduced proliferation is inhibited by ASODNs to ErbB-2, providing further support for a role of HRG as a mediator of MPA-induced growth. It has been previously reported that stable transfection of the human breast cancer cell line AU565 with antisense ErbB-2 cDNA results in decreased ErbB-3 protein expression (Hamburger and Yoo, 1997) . However, the results we now show demonstrate that in C4HD cells inhibition of ErbB-2 expression has no eect on protein levels of ErbB-3 or ErbB-4. Thus, it can be concluded that blocking HRG and MPA response by ErbB-2 ASODNs is the result of inhibiting the recruitment of ErbB-2 to a heterodimer complex with the other members of the ErbBs family, most likely with ErbB-3 since ErbB-4 expression levels are extremely low, that mediates HRG action in C4HD cells.
It has been previously found, in the human mammary epithelial cell line MCF-10A, that HRG acts as a dual speci®city growth factor able to drive signal transduction pathways that normally require both EGF and insulin-like growth factor-I (IGF-I) (Ram et al., 1995) . One possible explanation for this observation is that in MCF-10A cells that express ErbB-2, ErbB-3 and EGF-R, stimulation by HRG results in activation of signal transduction pathways that are normally activated separately by EGF and IGF-I. This may occur by the formation of heterodimers among ErbB family members that yield both EGF and IGF-I like signals. In this respect, it has been well documented that ErbB-3 possesses the unique capacity among the ErbB kinase family to bind and activate the p85 regulatory subunit of PI-3K (Carraway and Cantley, 1994; Fedi et al., 1994; Graus-Porta et al., 1997) . ErbB-3 has seven repeats of the Tyr-X-X-Met motif in its carboxy-terminal domain which is the p85 Src homology 2 (SH2) domain recognition sequence (Carraway and Cantley, 1994) . ErbB-3 ability to associate with PI-3K confers to this receptor the capacity to share signal transduction pathways with IGFs, since activation of type I IGF-R results in tyrosine phosphorylation of a substrate protein IRS-1, which in turn binds to and activates p85 (Backer et al., 1993) . PI-3K activation in mammary tumor cells treated with HRG (SeppLorenzino et al., 1996) or in mammary tumors that arise in transgenic mice overexpressing HRG (Amundadotir and Leder, 1998) has been reported. We have recently demonstrated, by blocking type I IGFs receptor expression using antisense oligodeoxynucleotides, that a functional type I IGF-R is essential for MPA-induced proliferation of C4HD cells (Elizalde et al., 1998) . Therefore, herein we have investigated whether HRG also requires a functional type I IGF-R for its mitogenic activity. The results we obtained blocking type I IGF-R and treating C4HD cells with HRG demonstrate, for the ®rst time according to our knowledge, that malignant mammary epithelial cells that overexpress ErbB-2 and ErbB-3 and express low levels of ErbB-4 cannot respond to HRG with mitogenesis in the absence of a functional type I IGF-R. This result excludes the possibility that in cells with high ErbB-3 levels such as C4HD, HRG through the activation of ErbB-3 could elicit signal transduction pathways shared with type I IGF-R, avoiding the necessity of an activated IGF-IR. A similar result has been reported showing that mouse embryo ®broblasts overexpressing EGF-R but lacking type I IGF-R do not respond to EGF-induced mitogenesis or transformation . Our results are consistent with the hypothesis that there is an interdependence between growth factor receptors and that type I IGF-R is downstream from the ErbB family of receptors, as predicted by the competence progression model of cell proliferation . It is noteworthy that abolishing type I IGF-R expression does not aect ErbBs receptor expression at protein level. Thus, it remains to be elucidated whether abolishing type I IGF-R aects HrG capacity to activate ErbBs through phosphorylation. In addition, recent ®ndings have indicated the existence of a mitogenic pathway for type I IGF-R which does not involve MAP kinase cascade or PI-3K activation (Barone and Courtneidge, 1995; Lowe et al., 1997) . Results from have shown that this pathway is not shared with PDGF and EGF receptors.
In conclusion, our results provide evidence of interactions between progestins and HRG signaling pathways in mammary tumors and demonstrate that a functional type I IGF-R is essential for the HRG proliferative eects in mammary tumor cells.
Materials and methods

Animals and tumors
Experiments were carried out in virgin female BALB/c mice raised at the National Academy of Medicine of Buenos Aires. All animal studies were conducted in accordance with the highest standards of animal care as outlined in the NIH guide for the Care and Use of Laboratory Animals. Hormonedependent ductal tumors (C4HD, D5HD and 53HD) originated in mice treated with 40 mg MPA every 3 months for a year, and have been maintained by serial transplantation in animals treated with 40 mg s.c. MPA depot on the opposite¯ank to tumor inoculum (Molinolo et al., 1987; Lanari et al., 1989) . Their hormone independent counterparts, C4HI, D5HI and 53HI, developed from HD tumors growing in mice that were not treated with MPA, approximately a year after the inoculum (Molinolo et al., 1987; Lanari et al., 1989) . These HI tumor lines have been maintained by serial transplantation in untreated female mice. Tumor lines C4HD, D5HD and 53HD are of ductal origin and express PR and ER (Molinolo et al., 1987; Lanari et al., 1989) . Although their respective HI counterparts C4HI, D5HI and 53HI have developed the capacity to grow in the absence of progestin treatment, they have retained PR and ER (Molinolo et al., 1987; Lanari et al., 1989) . HI lines 60, 55, 52B and 39 originated in MPA-treated mice and have been maintained by syngeneic transplants in untreated virgin female mice. They are of lobular origin and express EGF-R but not PR or ER (Lanari et al., 1989) .
Primary cultures and cell proliferation assays
Primary cultures of epithelial cells or ®broblasts from C4HD and 59HD tumors, growing in MPA-treated mice, were performed as previously described (Dran et al., 1995) . In brief, tumors were aseptically removed, minced and washed with DMEM/F12 (Dulbecco's modi®ed Eagle's medium: Ham's F12, 1 : 1, without phenol red, 100 U/ml penicillin and 100 mg/ml Streptomycin). The tissue was suspended in 5 ml of enzymatic solution [trypsin: 2.5 mg/ml, albumin: 5 mg/ml and collagenase type II (Gibco±BRL, Gaithersburg, MD): 239 U/ml] in phosphate buered saline (PBS) and incubated at 378C for 20 min, under continuous stirring. The liquid phase of the suspension was then removed and the undigested tissue was incubated with fresh enzymatic solution for 20 min. Enzyme action was stopped by adding DMEM/ F12+5% heat inactivated fetal calf serum (FCS) (Gen S.A., Buenos Aires). Epithelial and ®broblastic cells were separated as already described (Dran et al., 1995) . Brie¯y, the cell suspension was resuspended in 15 ml of DMEM/F12+10% FCS and allowed to sediment for 20 min. The upper 5 ml, corresponding to the ®broblastic fraction, was seeded in asks, and the cells were allowed to attach during 1 ± 2 h after which the medium containing unattached cells was removed and replaced by fresh DMEM/F12+10% FCS. The sedimented cells, corresponding to the epithelial enriched fraction, were resuspended again in 15 ml of DMEM/ F12+5% FCS and allowed to sediment for another 20 min. The upper 15 ml were discarded and this procedure was repeated until no ®broblasts were observed in the supernatant. Cells were plated in culture¯asks with DMEM/F12+5% steroid-stripped FCS (ChFCS) (Dran et al., 1995) and allowed to attach for 24 ± 48 h. Purity of the epithelial cultures was evaluated by cytokeratin staining. Cells were incubated in DMEM/F12, (without phenol red, 100 U/ ml penicillin, and 100 m/ml streptomycin), with 2.5% ChFCS in the presence or absence of MPA (10 nM and recombinant human HRGb1 (Neomarkers, Freemont, CA) at concentrations ranging from 0.02±200 ng/ml. After a 24 h incubation, 50% of media was replaced by fresh media and cells were incubated for another 24 h in the presence of 0.2 mCi of 3 Hthymidine (NEN, Dupont, Boston MA, USA; speci®c activity: 70 ± 90 Ci/mmol). Cells were then trypsinized and harvested. Assays were performed in octuplicate. The dierences between control and experimental groups were analysed by ANOVA followed by Tukey t-test between groups. In formed experiments we demonstrated that thymidine uptake correlates with the number of cells/well (Dran et al., 1995) .
Antisense studies
HRG antisense (5'-AGA CAT CTC GCC GAA GA) and sense (5'-TCT TCG GCG AGA TGT CT) oligodeoxynucleotides (ODNs) correspond to the rat HRG mRNA translation start (Yang et al., 1995) . In addition, a scrambled sequence (5'-CAG TGC CAA CAA GCG AT) with the same overall oligodeoxynucleotides content as the HRG antisense oligo was used. ErbB-2 antisense (5'-GGC CGC CAG CTC CAT) and sense (5'-ATG GAG CTG GCG GCC) ODNs have been previously described (Colomer et al., 1994) . Type I IGR-R antisense (5'-TCC TCC GGA GCC AGA CTT) and sense (5'-AAG TCT GGC TCC GGA GGA) ODNs correspond to codons 21 ± 26 of the signal sequence of the subunit of type I IGF-R preceding the proreceptor sequence. ODNs were purchased from CyberSyn (Lenni, PA, USA) or from NucleiCo (Buenos Aires, Argentina).
The eect of ODNs was studied as follows: in a Falcon 96-well microtitreplate, 0.2 ml/well of a suspension were seeded at a concentration of 10 5 cell/ml. After attachment (24 ± 48 h), the cells were incubated for 48 h with medium (serum used in antisense studies was heated at 658C for 30 min to inactivate exonucleases) containing the indicated concentrations of ODNs. The media were changed every 24 h adding fresh ODNs. After incubation, [ 3 H]thymidine was added and incorporation was determined as described above.
Mouse heregulin cloning and sequencing
Total RNA isolated from tumors using the guanidinium isothiocynate/phenol extraction method (Chomczynski and Sacchi, 1987) was reverse transcribed using oligodT to generate ®rst-strand cDNA (Perkin Elmer, Foster City, CA, USA) and used as a template with the following oligonucleotides:
5'-GCGAATGGGCCTCACCACCCAA-AC (5' primer) and 5'-TTCGCTATGAGGAGAGTCT-CTGT (3' primer) in a 35-cycle polymerase chain reaction (PCR) ampli®cation. With this pair of ODN we identi®ed a PCR fragment of 387 b.p. localized in the cytoplasmic domain of the gene. When the primers used were 5'-TGAAGAGCCAGGGTCAGCTGCAGG (5' primer) and 5'-AGACTCTGAGGACACATAGG (3' primer), that amplify the Ig domain of the gene, the fragment identi®ed was 333 b.p. long. Both pairs of oligodeoxynucleotides were chosen on the basis of the rat HRG sequence . Fragments were cloned in a pCRII vector using the TA Cloning kit (Invitrogene Corp, San Diego, CA, USA) and subsequently sequenced. Sequences were obtained using [ 
RNAse protection assay
The HRG probe was the 333 b.p. HRG cDNA fragment cloned in a pCRII vector (Invitrogene) and linearized with HindIII to provide the antisense riboprobe. The rpL32 human cDNA clone (encoding ribosomal protein L32) (Young and Trowsdale, 1985) was provided by Dr R Rochford (The Scripps Research Institute, La Jolla, CA, USA). This recombinant constructed in a pGem 4 vector (Promega, Madison, WI, USA) was linearized with EcoIR, providing a template for antisense riboprobe protecting a 76 b.p. mRNA fragment. The antisense 32 P-labeled RNA probes were transcribed with T7 RNA polymerase following manufacturer's protocol (Promega). Thirty mg of total RNA isolated as described (Chomczynski and Sacchi, 1987) were hybridized with 2610 5 c.p.m. of each probe in the conditions previously described (Guerra et al., 1996) , followed by digestion with RNase A (Sigma). All RNA samples were hybridized with HRG probe and rpL32 probe (used to correct for small variations in the amount of RNA loaded) simultaneously. Samples were extracted with phenol/ chloroform/isoamyl alcohol (20 : 20 : 1) and precipitated with 20 mg of tRNA (Sigma) and 2 v of absolute ethanol. The pellets were resuspended in 5 ml of an 80% formamide loading buer and run on a 6% polyacrylamide sequencing gel with 8 M urea. Size markers were prepared by end labeling MspI-digested fragments of pBR322 plasmid. Band intensities were quantitated by scanning multiple autoradiograms of various exposures.
ErbBs and HRG Western blotting
In order to study expression of ErbB receptors, lysates were prepared from C4HD cells growing in medium with 2.5% ChFCS. After washing in ice-cold PBS, cells were lysed in buer containing 20 mM Tris (pH 7.4), 0.1 M NaCl, 5 mM MgCl 2 , 1% Nonidet P-40, 0.1% b-mercaptoethanol, 1 mM phenylmethylsulfonyl¯uoride (PMSF), 10 mg/ml leupeptin, 5 mg/ml pepstatin, 5 mg/ml aprotinin, 1 mM sodium orthovanadate, 5 mM NaF, 20 mM sodium molybdate and 5 mM sodium pyrophosphate. Cell lysates were centrifuged at 40 000 g for 40 min at 48C and protein content in the supernatant was determined using a Bio-Rad kit (Richmond, CA, USA). Proteins were solubilized in sample buer (60 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol and 0.01% bromophenol blue) and subjected to SDS ± PAGE on a 6% gel. Proteins were electroblotted on to nitrocellulose. Membrane was blocked with PBS, 0.1% Tween 20 (PBST) and immunoblotted with the following antibodies: ErbB-2 rabbit polyclonal antibody Neu C-18 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), ErbB-3 rabbit polyclonal antibody C-17 (Santa Cruz Biotechnology), ErbB-4 rabbit polyclonal antibody C-18 (Santa Cruz Biotechnology), and ErbB-4/HER-4 Oncoprotein Ab-2 rabbit polyclonal antibody (Neomarkers, Freemont, CA, USA). After washing, the membranes were incubated with HRP-conjugated secondary antibody (Amersham International, UK), Enhanced chemiluminescence (ECL) was performed according to manufacturer's instructions (Amersham).
For studying the eect of ASODs to ErbB-2 mRNA or to HRG mRNA on protein expression, lysates were prepared as described above from cells growing in 2.5% ChFCS or 10 nM MPA and from cells growing in 10 nM MPA+ODNs. Rabbit polyclonal anti-HRG antibody, speci®c for HRG precursor (C-20, Santa Cruz Biotechnology) was used in HRG studies.
ErbB receptor tyrosine phosphorylation analysis
Lysates from C4-HD cells growing in 2.5% ChFCS, and from cells treated for 48 h with 10 nM MPA or 2 ng/ml of HRG were prepared as described above. Immunoprecipitations were performed on 200 mg of total cell protein. All lysates were precleared with Protein A-Agarose (Santa Cruz Biotechnology) and 2 mg of ErbB-2 Neu C-18 or ErbB-3 C17 antibodies (Santa Cruz Biotechnology) were used. Immunoprecipitations were rocked 2 h at 48C and then the immunocomplexes were captured by adding Protein AAgarose and rocked for an additional 2 h. Beads were washed three times with lysis buer, then boiled for 10 min in sample buer and subjected to SDS ± PAGE on a 6% gel. Proteins were electroblotted on to nitrocellulose. Membranes were blocked with PBS, 0.1% Tween 20 (PBST), 5% bovine serum albumin (Sigma) and 1% ovoalbumin (Sigma) and ®lters were probed with mouse monoclonal Anti-P-Tyr PY-20 (Santa Cruz Biotechnology). Proteins were visualized with HRP-conjugated secondary antibody, using ECL detection (Amersham). Identical aliquots of each immunoprecipitate were subjected to immunoblot analysis with anti-ErbB-2 or anti-ErbB-3 antibodies to verify that nearly equal amounts of proteins immunoprecipitated were loaded.
IGF-I receptor binding assay
Recombinant human IGF-I, kindly provided by Dr James Merryweather (Chiron, Emeryville, CA, USA), was iodinated and puri®ed as descried (Guerra et al., 1996) . Binding to intact cell monolayers from C4-HD epithelial cells, treated with ODNs, to IGF-IR was performed as described (Elizalde et al., 1998) . Assays were performed in triplicate and results were analysed by the Scatchard method (1949) .
